

proTract®

For infants with eczema

PRODUCT INFORMATION SHEET



The active ingredient in proTract® for Atopic Dermatitis is PCC®, a strain of the probiotic *Lactobacillus fermentum* that has been tested in a clinical study in infants suffering with symptoms of moderate to severe atopic dermatitis (eczema).

Relieves symptoms

Supports immunity

Safe for infants

PROTRACT® FOR ATOPIC DERMATITIS MAY ALSO ASSIST IN:

- ✓ Managing the symptoms of moderate to severe eczema in infants
- ✓ Maintaining a healthy immune system

INTRODUCING PROTRACT®

proTract® for Atopic Dermatitis, is a formulation of PCC® in openable capsules for infants from 6-18 months who are suffering symptoms of atopic dermatitis, or eczema. This formulation was used in an Australian clinical study that examined the ability of PCC® to manage the symptoms of moderate to severe atopic dermatitis in infants when given daily (by sprinkling it on their food) for 8 weeks.

WHAT IS ATOPIC DERMATITIS?

Atopic dermatitis, also known as eczema, is an inflammatory skin disease caused by an allergic reaction. The signs of atopic dermatitis appear early in life (from 6 months of age) and include dry and scaly patches on the body and face, especially the cheeks. These symptoms pose a significant burden on healthcare resources and on the child's quality of life.

DID YOU KNOW?

Atopic dermatitis is very common, affecting as many as 1 child in 5 (20%) in many countries, including Australia, the UK, New Zealand, Singapore, and parts of the US.

Symptoms are measured by doctors using the Severity Scoring of Atopic Dermatitis (SCORAD) index.


The active ingredient in proTract® for Atopic Dermatitis is PCC®, Bioxyne's patented strain of the probiotic *Lactobacillus fermentum*. Probiotics are live bacteria that, when administered in adequate amounts, provide a health benefit for the consumer. Usually they are members of the *Lactobacillus* or *Bifidobacteria* families. The mechanism by which probiotics function to impact human health is thought to be related to their ability to alter the composition of the gut microbiota and modulate the human immune system. Given the extensive involvement of the immune system in atopic dermatitis, Bioxyne considered it was likely that PCC® may provide an option for management of symptoms, and so we conducted a clinical trial at the University of Western Australia.

REFERENCES

- Weston S, Halbert A, Richmond P, Prescott SL, 2005. Effects of probiotics on atopic dermatitis: a randomised controlled trial. *Archives of Diseases in Childhood* 90:892-897. (Sponsor: Probiomics Limited)
- Prescott S, Dunstan JA, Hale J, Breckler, Lehmann LH, Weston S, Richmond P, 2005. Clinical effects of probiotics are associated with increased interferon-gamma responses in very young children with atopic dermatitis. *Clinical & Experimental Allergy*; 35(12):1557-1564. (Sponsor: Probiomics Limited)

CLINICAL AND SCIENTIFIC RESEARCH

The researchers in Western Australia reported that those infants (aged 6 to 18 months) who were given PCC® daily for 8 weeks generally had fewer AD symptoms compared to those given a placebo^{1,2}:



The above graphs from the Western Australian study show baseline and week 16 SCORAD index scores (a measure of symptom severity) for each participant in the placebo and probiotic (PCC®) groups of infants with atopic dermatitis symptoms.

The blue dots mark the participants whose symptoms worsened over the 16 weeks of the trial.

Who should use proTract?

Young child suffering from the symptoms of atopic dermatitis, (eczema). For infants aged 6-18 months.

Directions

Open one capsule twice a day and sprinkle it on to 8 weeks. If symptoms persist, see your doctor.